Ambrilia Biopharma Incorporated - Earning & Dividend Analysis Snapshot

This detailed Report provides an Earnings and Dividends history for Ambrilia Biopharma Incorporated. Tabular results include up to a ten-year history of "as reported" Earnings per Share and Dividends per Share plus a calculation of the amount of earnings paid out over the year in dividends (i.e. Payout Ratio). Earnings and Dividends are presented on both a Quarterly and Annual basis. An annual Percent Change factor is calculated for both Earnings and Dividends.

Ambrilia Biopharma Incorporated. The Group's principal activity is to develop and commercialize diagnostics and therapeutic drugs. This biopharmaceutical Group develops innovative therapeutics in the fields of oncology and infectious diseases. Its product portfolio includes PCK3145, a non-toxic peptide for the treatment of advanced metastatic prostate cancer; TVT-Dox, a tumor vasculature targeting technology for the treatment of solid tumors; Octreotide, an easily reconstituted prolonged-release formulation for the treatment of acromegaly and some digestive tumors; Goserelin, a potential prolonged-release formulation for the treatment of hormone-sensitive prostate cancer; PPL-100, a protease inhibitor for the treatment of HIV/AIDS currently in Phase I clinical trials; SPC3, a fusion inhibitor for the treatment of HIV/AIDS which is at the preclinical stage.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report